| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4848283
Max Phase: Preclinical
Molecular Formula: C19H16Cl2N2O2
Molecular Weight: 375.26
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: Cc1ccc(-n2nc(CCC(=O)O)cc2-c2cc(Cl)cc(Cl)c2)cc1
Standard InChI: InChI=1S/C19H16Cl2N2O2/c1-12-2-5-17(6-3-12)23-18(11-16(22-23)4-7-19(24)25)13-8-14(20)10-15(21)9-13/h2-3,5-6,8-11H,4,7H2,1H3,(H,24,25)
Standard InChI Key: NFHUNGNFEGORNW-UHFFFAOYSA-N
Associated Targets(Human)
Retinoid X receptor alpha 3637 Activities
Retinoid X receptor beta 726 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Retinoid X receptor gamma 646 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 375.26 | Molecular Weight (Monoisotopic): 374.0589 | AlogP: 5.17 | #Rotatable Bonds: 5 |
| Polar Surface Area: 55.12 | Molecular Species: ACID | HBA: 3 | HBD: 1 |
| #RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 4.14 | CX Basic pKa: 1.26 | CX LogP: 5.30 | CX LogD: 2.23 |
| Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.67 | Np Likeness Score: -1.09 |
References
| 1. Schierle S, Chaikuad A, Lillich FF, Ni X, Woltersdorf S, Schallmayer E, Renelt B, Ronchetti R, Knapp S, Proschak E, Merk D.. (2021) Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics., 64 (8.0): [PMID:33793232] [10.1021/acs.jmedchem.1c00235] |
Source
Source(1):